Evaxion Biotech A/SEVAX
13F holders, Q4 2024 (December 31)9holders +1
2new positions
2sold out
1famous investor
$0.84avg. 13F price*
At the end of Q4 2024, 9 institutions reported holding Evaxion Biotech A/S (EVAX) in their 13F filings, up 1 from Q3 2024. 2 opened new positions and 2 sold out. The largest holders were Merck & Co., Inc. ($458K), Armistice Capital, LLC ($127K) and Invst, LLC ($43K). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Evaxion Biotech A/S
- CUSIP
- 29970R204
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $48K |
| Exits | 2 | $51K |
All 13F filers, Q3 2024 → Q4 2024: 64,605 shares bought and 348,875 shares sold, net −284,270 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Merck & Co., Inc. | 0.18% | — | 542,279 | $458K |
| Armistice Capital, LLC | 0.00% | Reduce -68.8% | 150,462 | $127K |
| Invst, LLC | 0.01% | Add +16.7% | 50,400 | $43K |
| Catalina Capital Group, LLC | 0.01% | New | 34,864 | $29K |
| Millennium Management | 0.00% | New | 22,541 | $19K |
| Beacon Capital Management, LLC | 0.00% | No change | 4,863 | $4K |
| JPMorgan Chase & Co. | 0.00% | No change | 780 | $650 |
| Rhumbline Advisers | 0.00% | No change | 290 | $240 |
| SouthState Bank Corp | 0.00% | No change | 4 | $3 |
"% of holder's portfolio" is EVAX's weight in each manager's 13F, not the share of Evaxion Biotech A/S the manager owns.